News Releases

SAN DIEGO and VANCOUVER, British Columbia, Jan. 30, 2017 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) a biopharmaceutical company developing topsalysin (PRX302) for the treatment of urological diseases, today announced that Randall E. Woods, president and chief executive officer, will present a corporate overview at the BetterInvesting™ Virtual Investor Conference. The presentation will take place on Thursday February 2, 2017 at 1:00 p.m. Eastern Time.

The presentation will be webcast live at http://tinyurl.com/0202prepr and can also be accessed through the Investor Relations page at www.sophiris.com. A replay of the presentation will be available on the Company's website for 90 days.  

Recent Company Highlights

• In August 2016, Sophiris raised net proceeds of $27.4 million to fund a Phase 2b clinical trial for the treatment of localized prostate cancer and working capital and general corporate purposes.
• In June 2016, Sophiris completed a Phase 2a proof of concept trial of topsalysin in localized prostate cancer in which topsalysin demonstrated the ability to ablate tumor cells in 50 percent of patients, including two men who experienced complete ablation of their targeted tumor with no evidence of any tumor remaining at 6 months post treatment.
• In May 2016, Sophiris presented complete results from a Phase 3 BPH study at the AUA 2016 Annual Meeting demonstrating that topsalysin met the primary endpoint of a reduction in symptom score compared to the vehicle control arm.

About Sophiris 
Sophiris Bio Inc. is a biopharmaceutical company developing topsalysin, a clinical-stage, targeted therapy for the treatment of urological diseases. Topsalysin has successfully completed a Phase 2a clinical trial for the treatment of localized low to intermediate risk prostate cancer. Topsalysin has also successfully completed a Phase 3 clinical study for the treatment of the symptoms of benign prostatic hyperplasia (BPH), and is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. For more information, please visit www.sophiris.com.

About VirtualInvestorConferences.com
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform.

Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.

Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on Sophiris' current beliefs as well as assumptions made by and information currently available to Sophiris and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by Sophiris in its public securities filings; actual events may differ materially from current expectations. Sophiris disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Sophiris Bio Inc